Promises, promises..

Annals of Neurology

Volumn 61, Issue 1, 2007, Pages 1-2

  Thompson, Alan J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; DISEASE COURSE; EDITORIAL; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; REMISSION;

CLINICAL TRIALS; HUMANS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; TREATMENT FAILURE;

EID: 33846846455     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21083     Document Type: Editorial

References (21)

1. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. A review. Brain 1997;120:1085-1096.
2. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
3. Rovaris M, Bozzali M, Santuccio G, et al. In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain 2001;124:2540-2549.
4. Nijeholt GJ, van Walderveen MA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subrypes and symptoms. Brain 1998;121:687-697.
5. Revesz T, Kidd D, Thompson AJ, et al. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994;117:759-765.
6. Lucchinetti C, Brück W, ParisI J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
7. Brück W, Lucchinetti C, Lassmann H. The pathology of primary progressive multiple sclerosis. Mult Scler 2002;8:93-97.
8. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000;47:831-835.
9. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
10. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria." Ann Neurol 2005;58:840-846.
11. Leary SM, Miller DH, Stevenson VL. Interferon β-1A in primary progressive multiple sclerosis: an exploratory randomized controlled trial. Neurology 2003;60:44-51.
12. Montalban X. Overview of European pilot study of interferon β-1b in primary progressive multiple sclerosis. Mult Scler 2004;10(suppl 1):S62-S64.
13. Leary SM, Thompson AJ. Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs 2005;19:369-376.
14. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24.
15. Wolinsky JS, Narayana PA, He R. Overview of treatment trials: early baseline clinical and MRI data of the PROMiSe trial. In: Filippi M, Comi G, eds. Primary progressive multiple sclerosis. Milan, Italy: Springer-Verlag Italia, 2002.
16. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-146.
17. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology 2005;65:1919-1923.
18. Abrams KR. Monitoring randomized controlled trials. BMJ 1998;316:1183-1184.
19. Noseworthy J, O'Brien P, Mayo Clinic-Canadian Cooperative MS Study Group. The Mayo Clinic Canadian Cooperative trial of Sulfasalazine in active multiple sclerosis. Neurology 1998;51:1342-1352.
20. Matthews PM. Primary progressive multiple sclerosis takes centre stage. J Neurol Neurosurg Psychiatry 2004;75:1232-1233.
21. McFarland HF, Reingold SC, on behalf of National MS Society Advisory Committee on Clinical Trials of New Agents in MS. The future of MS therapies: redesigning MS clinical trials in a new therapeutic era. Mult Scler 2005;11:669-676.